We want to share the acknowledgment that APICES has received in PRISMA-1 study, which is a phase II bladder cancer trial, published in the ASCO GU 2025 congress, in which APICES has collaborated in start-up, project management, and medical writing activities.
This means a great motivation to all the APICES team to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank Gilead, Dr. Ignacio Duran Martínez, and Fupocan for giving us the opportunity to appear in the acknowledgments of the publication and congratulate them and all the investigators for their project success.
This phase II clinical trial aims to evaluate perioperative immunotherapy combined with sacituzumab in patients with muscle-invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy.
You can find further information in the following link: Program Guide – ASCO Meeting Program Guide
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
